Therapeutic targeting of histone modifications in adult and pediatric high-grade glioma

Frontiers in Oncology

Volumn 7, Issue MAR, 2017, Pages

  Williams, Maria J ^a   Singleton, Will G B ^a   Lowis, Stephen P ^b   Malik, Karim ^c   Kurian, Kathreena M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Diffuse intrinsic brainstem glioma; Epigenetics; Glioblastoma multiforme; High grade glioma; Histone acetylation; Histone deacetylase inhibitors; Histone methylation

Indexed keywords

BEVACIZUMAB; BMI1 PROTEIN; BORTEZOMIB; ENZASTAURIN; ERLOTINIB; GLYCINE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; ISOCITRATE DEHYDROGENASE 1; LYSINE DERIVATIVE; MESSENGER RNA; METHYLTRANSFERASE; PANOBINOSTAT; POLYCOMB REPRESSIVE COMPLEX 2; ROMIDEPSIN; TEMOZOLOMIDE; TRANSCRIPTION FACTOR EZH2; VALPROIC ACID; VORINOSTAT;

ALPHA THALASSEMIA; ANOREXIA; CELL DIFFERENTIATION; CHONDROBLASTOMA; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GIANT CELL TUMOR; GLIOBLASTOMA; GLIOMA; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HYPERTRIGLYCERIDEMIA; LOSS OF FUNCTION MUTATION; MAXIMUM TOLERATED DOSE; MENTAL RETARDATION MALFORMATION SYNDROME; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN PROCESSING; REVIEW; SENSORY NEUROPATHY; TELOMERE HOMEOSTASIS; THROMBOCYTOPENIA; UPREGULATION;

EID: 85017174050     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2017.00045     Document Type: Review

References (104)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 114(2):97-109. doi: 10.1007/s00401-007-0243-4
2. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol (2014) 16(Suppl 4):iv1-63. doi:10.1093/neuonc/nou223
3. Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol (2012) 2:105. doi:10.3389/fonc.2012.00105
4. Broniscer A. Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest (2006) 24(1):77-81. doi:10.1080/07357900500449702
5. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer (2004) 4(2):143-53. doi:10.1038/nrc1279
6. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 352(10):997-1003. doi:10.1056/NEJMoa043331
7. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell (2007) 128(4):707-19. doi:10.1016/j.cell.2007.01.015
8. Hake SB, Garcia BA, Duncan EM, Kauer M, Dellaire G, Shabanowitz J, et al. Expression patterns and post-translational modifications associated with mammalian histone H3 variants. J Biol Chem (2006) 281(1):559-68. doi:10.1074/jbc.M509266200
9. Jang C-W, Shibata Y, Starmer J, Yee D, Magnuson T. Histone H3.3 maintains genome integrity during mammalian development. Genes Dev (2015) 29(13):1377-92. doi:10.1101/gad.264150.115
10. Szenker E, Ray-Gallet D, Almouzni G. The double face of the histone variant H3.3. Cell Res (2011) 21(3):421-34. doi:10.1038/cr.2011.14
11. Berger SL. The complex language of chromatin regulation during transcription. Nature (2007) 447(7143):407-12. doi:10.1038/nature05915
12. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 10(7):457-69. doi:10.1038/nrc2876
13. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E, Jacob K, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature (2012) 482(7384):226-31. doi:10.1038/nature10833
14. Talbert PB, Henikoff S. Histone variants [mdash] ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol (2010) 11(4):264-75. doi:10.1038/nrm2861
15. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone. Nat Genet (2013) 45(12):1479-82. doi:10.1038/ng.2814
16. Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 124(3):439-47. doi:10.1007/s00401-012-0998-0
17. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 125(2):315-26. doi:10.1016/j.cell.2006.02.041
18. Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet (2009) 41(3):376-81. doi:10.1038/ng.322
19. Bjerke L, Mackay A, Nandhabalan M, Burford A, Jury A, Popov S, et al. Histone H3.3 mutations drive paediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 3(5):512-9. doi:10.1158/2159-8290.CD-12-0426
20. Gielen GH, Gessi M, Hammes J, Kramm CM, Waha A, Pietsch T. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas. Am J Clin Pathol (2013) 139(3):345-9. doi:10.1309/AJCPABOHBC33FVMO
21. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 44(3):251-3. doi:10.1038/ng.1102
22. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 321(5897):1807. doi:10.1126/science.1164382
23. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones David TW, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 22(4):425-37. doi:10.1016/j.ccr.2012.08.024
24. Ku M, Koche RP, Rheinbay E, Mendenhall EM, Endoh M, Mikkelsen TS, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet (2008) 4(10):e1000242. doi:10.1371/journal.pgen.1000242
25. Su IH, Dobenecker M-W, Dickinson E, Oser M, Basavaraj A, Marqueron R, et al. Polycomb group protein Ezh2 controls actin polymerization and cell signaling. Cell (2005) 121(3):425-36. doi:10.1016/j.cell.2005.02.029
26. Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 340(6134):857-61. doi:10.1126/science.1232245
27. Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol (2013) 23(5):558-64. doi:10.1111/bpa.12042
28. Bender S, Tang Y, Lindroth Anders M, Hovestadt V, Jones David TW, Kool M, et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell (2013) 24(5):660-72. doi:10.1016/j.ccr.2013.10.006
29. Chan K-M, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev (2013) 27(9):985-90. doi:10.1101/gad.217778.113
30. Fontebasso AM, Schwartzentruber J, Khuong-Quang D-A, Liu X-Y, Sturm D, Korshunov A, et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. Acta Neuropathol (2013) 125(5):659-69. doi:10.1007/s00401-013-1095-8
31. Saratsis A, Kambhampati M, Snyder K, Yadavilli S, Devaney J, Harmon B, et al. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol (2014) 127(6):881-95. doi:10.1007/s00401-013-1218-2
32. Swartling FJ, Savov V, Persson AI, Chen J, Hackett CS, Northcott PA, et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell (2012) 21(5):601-13. doi:10.1016/j.ccr.2012.04.012
33. Fontebasso AM, Liu X-Y, Sturm D, Jabado N. Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol (2013) 23(2):210-6. doi:10.1111/bpa.12023
34. Dhayalan A, Tamas R, Bock I, Tattermusch A, Dimitrova E, Kudithipudi S, et al. The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9. Hum Mol Genet (2011) 20(11):2195-203. doi:10.1093/hmg/ddr107
35. Lewis PW, Elsaesser SJ, Noh K-M, Stadler SC, Allis CD. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A (2010) 107(32):14075-80. doi:10.1073/pnas.1008850107
36. Pathak P, Jha P, Purkait S, Sharma V, Suri V, Sharma MC, et al. Altered global histone-trimethylation code and H3F3A-ATRX mutation in pediatric GBM. J Neurooncol (2015) 121(3):489-97. doi:10.1007/s11060-014-1675-z
37. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 333(6041):425. doi:10.1126/science.1207313
38. Lee J, Solomon DA, Tihan T. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol (2017) 132(1):1-11. doi:10.1007/s11060-016-2349-9
39. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 118(4):469-74. doi:10.1007/s00401-009-0561-9
40. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov (2013) 3(7):730-41. doi:10.1158/2159-8290.CD-13-0083
41. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol (2008) 116(6):597-602. doi:10.1007/s00401-008-0455-2
42. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 360(8):765-73. doi:10.1056/NEJMoa0808710
43. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 462(7274):739-44. doi:10.1038/nature08617
44. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 17(5):510-22. doi:10.1016/j.ccr.2010.03.017
45. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 483(7390):474-8. doi:10.1038/nature10860
46. Gallo M, Coutinho Fiona J, Vanner Robert J, Gayden T, Mack Stephen C, Murison A, et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell (2015) 28(6):715-29. doi:10.1016/j.ccell.2015.10.005
47. Sebastian S, Sreenivas P, Sambasivan R, Cheedipudi S, Kandalla P, Pavlath GK, et al. MLL5, a trithorax homolog, indirectly regulates H3K4 methylation, represses cyclin A2 expression, and promotes myogenic differentiation. Proc Natl Acad Sci U S A (2009) 106(12):4719-24. doi:10.1073/pnas.0807136106
48. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature (2012) 483(7390):479-83. doi:10.1038/nature10866
49. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 19(1):17-30. doi:10.1016/j.ccr.2010.12.014
50. Takai H, Masuda K, Sato T, Sakaguchi Y, Suzuki T, Suzuki T, et al. 5-hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex. Cell Rep (2014) 9(1):48-60. doi:10.1016/j.celrep.2014.08.071
51. Guo Junjie U, Su Y, Zhong C, Ming G-L, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell (2011) 145(3):423-34. doi:10.1016/j.cell.2011.03.022
52. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst (2011) 103(2):143-53. doi:10.1093/jnci/djq497
53. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res (2009) 15(19):6002-7. doi:10.1158/1078-0432.CCR-09-0715
54. Dawson Mark A, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell (2012) 150(1):12-27. doi:10.1016/j.cell.2012.06.013
55. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol (2012) 90(1):85-94. doi:10.1038/icb.2011.100
56. Boyer LA, Latek RR, Peterson CL. The SANT domain: a unique histone-tail-binding module? Nat Rev Mol Cell Biol (2004) 5(2):158-63. doi:10.1038/nrm1314
57. Reichert N, Choukrallah M-A, Matthias P. Multiple roles of class I HDACs in proliferation, differentiation, and development. Cell Mol Life Sci (2012) 69(13):2173-87. doi:10.1007/s00018-012-0921-9
58. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res (2007) 5(10):981-9. doi:10.1158/1541-7786.MCR-07-0324
59. Lagger G, O'Carroll D, Rembold M, Khier H, Tischler J, Weitzer G, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J (2002) 21(11):2672-81. doi:10.1093/emboj/21.11.2672
60. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 26(37):5541-52. doi:10.1038/sj.onc.1210620
61. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell (2002) 110(4):479-88. doi:10.1016/S0092-8674(02)00861-9
62. Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol (2009) 19(3):188-97. doi:10.1016/j.semcancer.2009.02.005
63. Bezecny P. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience. Med Oncol (2014) 31(6):1-15. doi:10.1007/s12032-014-0985-5
64. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell (2013) 155(2):462-77. doi:10.1016/j.cell.2013.09.034
65. Lucio-Eterovic AKB, Cortez MAA, Valera ET, Motta FJN, Queiroz RGP, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer (2008) 8:243. doi:10.1186/1471-2407-8-243
66. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett (2009) 280(2):168-76. doi:10.1016/j.canlet.2008.10.047
67. Kim YZ. Altered histone modifications in gliomas. Brain Tumor Res Treat (2014) 2(1):7-21. doi:10.14791/btrt.2014.2.1.7
68. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer (2004) 112(1):26-32. doi:10.1002/ijc.20395
69. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report. J Clin Oncol (2010) 28(22):3623-9. doi:10.1200/JCO.2009.25.9119
70. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group Phase 1 Consortium Study. Pediatr Blood Cancer (2013) 60(9):1452-7. doi:10.1002/pbc.24541
71. Institute. NC. Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme. Bethesda, MD: National Library of Medicine (2000). Available from: https://clinicaltrials.gov/ct2/show/NCT00731731
72. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, et al. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL0916). Pediatr Blood Cancer (2013) 60(3):390-5. doi:10.1002/pbc.24271
73. Su JM, Li X-N, Thompson P, Ou C-N, Ingle AM, Russell H, et al. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res (2011) 17(3):589-97. doi:10.1158/1078-0432.CCR-10-0738
74. Jack Su BCoM. Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children with High Grade Gliomas or Diffuse Intrinsic Pontine Glioma. Bethesda, MD: National Library of Medicine (2000). Available from: https://clinicaltrials.gov/show/NCT00879437
75. NCI. Vorinostat, Temozolomide, or Bevacizumab in Combination with Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients with Newly Diagnosed High-Grade Glioma. Bethesda, MD: National Library of Medicine (2000). Available from: https://clinicaltrials.gov/ct2/show/NCT01236560
76. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol (2009) 27(12):2052-8. doi:10.1200/JCO.2008.19.0694
77. Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a North Central Cancer Treatment Group Study. Neuro Oncol (2012) 14(2):215-21. doi:10.1093/neuonc/nor198
78. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Alfred Yung WK, Gilbert MR, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol (2011) 13(5):509-16. doi:10.1093/neuonc/nor017
79. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, et al. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol (2012) 107(1):133-8. doi:10.1007/s11060-011-0717-z
80. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol (2015) 17(6):862-7. doi:10.1093/neuonc/nou350
81. Shi W, Werner-Wasik M, Andrews DW, Evans JJ, Glass J, Kim L, et al. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. J Neurooncol (2016) 127(3):535-9. doi:10.1007/s11060-016-2059-3
82. Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys (2015) 92(5):986-92. doi:10.1016/j.ijrobp.2015.04.038
83. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol (2008) 26(34):5603-9. doi:10.1200/JCO.2008.18.0612
84. Peereboom D, Shepard D, Ahluwalia M, Brewer C, Agarwal N, Stevens GJ, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2010) 98(1):93-9. doi:10.1007/s11060-009-0067-2
85. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2009) 27(4):579-84. doi:10.1200/JCO.2008.18.9639
86. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, et al. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol (2010) 12(10):1071-7. doi:10.1093/neuonc/noq071
87. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol (2011) 13(12):1331-8. doi:10.1093/neuonc/nor130
88. Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology (2011) 77(12):1156-64. doi:10.1212/WNL.0b013e31822f02e1
89. Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Herndon JE, Coan AD, et al. Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: a phase I/II trial. J Clin Oncol (2012) 30(Suppl):abstr 2027
90. H. Lee Moffitt Cancer Center and Research Institute. A Phase I Trial of Vorinostat in Combination with Bevacizumab & Irinotecan in Recurrent Glioblastoma. Bethesda, MD: National Library of Medicine (2000). Available from: https://clinicaltrials.gov/ct2/show/NCT00762255
91. NCI. Vorinostat Combined with Isotretinoin and Chemotherapy in Treating Younger Patients with Embryonal Tumors of the Central Nervous System. Bethesda, MD: National Library of Medicine (2000). Available from: https://clinicaltrials.gov/ct2/show/NCT00867178
92. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res (2012) 18(21):6032-9. doi:10.1158/1078-0432.CCR-12-1841
93. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med (2014) 20(12):1394-6. doi:10.1038/nm.3716
94. Morales La Madrid A, Hashizume R, Kieran MW. Future clinical trials in DIPG: bringing epigenetics to the clinic. Front Oncol (2015) 5:148. doi:10.3389/fonc.2015.00148
95. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily M-A, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med (2015) 21(6):555-9. doi:10.1038/nm0715-827a
96. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer (2006) 6(11):846-56. doi:10.1038/nrc1991
97. Ciarapica R, Carcarino E, Adesso L, De Salvo M, Bracaglia G, Leoncini PP, et al. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer (2014) 14(1):139. doi:10.1186/1471-2407-14-139
98. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 100(20):11606-11. doi:10.1073/pnas.1933744100
99. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 419:624-9. doi:10.1038/nature01075
100. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 107(49):20980-5. doi:10.1073/pnas.1012525107
101. Liu B-L, Cheng J-X, Zhang X, Wang R, Zhang W, Lin H, et al. Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol Biomarkers Prev (2010) 19(11):2888. doi:10.1158/1055-9965.EPI-10-0454
102. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet (2014) 46(5):457-61. doi:10.1038/ng.2925
103. Kaplan FS, Xu M, Seemann P, Connor M, Glaser DL, Carroll L, et al. Classic and atypical FOP phenotypes are caused by mutations in the BMP type I receptor ACVR1. Hum Mutat (2009) 30(3):379-90. doi:10.1002/humu.20868
104. Veringa SJE, Biesmans D, van Vuurden DG, Jansen MHA, Wedekind LE, Horsman I, et al. In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One (2013) 8(4):e61512. doi:10.1371/journal.pone.0061512